News
-
-
PRESS RELEASE
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
Immunic completes enrollment for Phase 3 ENSURE trials in Relapsing MS and presents positive Phase 2 CALLIPER trial data in Progressive MS, showcasing vidofludimus calcium's potential. Top-line data in 2026 -
-
-
-
-
-
PRESS RELEASE
Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
Immunic announces positive results from Phase 2 CALLIPER trial showing 30% reduced risk of disability worsening in Primary Progressive Multiple Sclerosis patients with vidofludimus calcium. Webcast scheduled for April 30 -
-
